Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 10/2010

01-10-2010 | Article

Impact of antibiotic therapy on systemic cytokine expression in pneumococcal pneumonia

Authors: S. Padrones, C. Garcia-Vidal, S. Fernández-Serrano, A. Fernández, C. Masuet, J. Carratalà, M. Coromines, C. Ardanuy, F. Gudiol, F. Manresa, J. Dorca

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 10/2010

Login to get access

Abstract

The aim of this study was to compare the evolution of systemic cytokine levels over time in patients with pneumococal pneumonia treated either with β-lactam monotherapy or with combination therapy (β-lactam plus fluoroquinolone). Prospective observational study of hospitalized non-immunocompromised adults with PP. Concentrations of IL-6, IL-8, IL-10, and TNF-α were determined on days 0, 1, 2, 3, 5, and 7. Patients on β-lactam monotherapy were compared with those receiving combination therapy. Fifty-two patients were enrolled in the study. Concentrations of IL-6, IL-8, and IL-10 decreased rapidly in the first days after admission, in accordance with the mean time to defervescence. High levels of IL-6 were found in patients with the worst outcomes, measured by the need for intensive care unit admission and mortality. No major differences in demographic or clinical characteristics or severity of disease were found between patients treated with β-lactam monotherapy and those treated with combination therapy. IL-6 levels fell more rapidly in patients with combination therapy in the first 48 h (p = 0.016). Our data suggest that systemic expression of IL-6 production in patients with PP correlates with prognosis. Initial combination antibiotic therapy produces a faster decrease in this cytokine in the first 48 h.
Literature
1.
go back to reference Ardanuy C, Tubau F, Pallarés R et al (2009) Epidemiology of invasive pneumococcal disease among adult patients in Barcelona before and after pediatric 7-valent pneumococcal conjugate vaccine introduction 1997–2007. Clin Infect Dis 48:57–64CrossRefPubMed Ardanuy C, Tubau F, Pallarés R et al (2009) Epidemiology of invasive pneumococcal disease among adult patients in Barcelona before and after pediatric 7-valent pneumococcal conjugate vaccine introduction 1997–2007. Clin Infect Dis 48:57–64CrossRefPubMed
2.
go back to reference Barlett JG, Mundy LM (1995) Community-acquired pneumonia. N Engl J Med 333:1618–1624CrossRef Barlett JG, Mundy LM (1995) Community-acquired pneumonia. N Engl J Med 333:1618–1624CrossRef
3.
go back to reference Rosón B, Carratalà J, Dorca J et al (2001) Etiology, reasons for hospitalization, risk classes and outcomes of patients with community-acquired pneumonia hospitalized on the basis of conventional admission criteria. Clin Infect Dis 33:158–165CrossRefPubMed Rosón B, Carratalà J, Dorca J et al (2001) Etiology, reasons for hospitalization, risk classes and outcomes of patients with community-acquired pneumonia hospitalized on the basis of conventional admission criteria. Clin Infect Dis 33:158–165CrossRefPubMed
4.
go back to reference Feikin DR, Schuchat A, Kolczak M (2000) Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995–1997. Am J Public Health 90:223–229CrossRefPubMed Feikin DR, Schuchat A, Kolczak M (2000) Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995–1997. Am J Public Health 90:223–229CrossRefPubMed
5.
go back to reference Garcia-Vidal C, Fernández-Sabé N, Carratalà J et al (2008) Early mortality in patients with community-acquired pneumonia: causes and risk factors. Eur Respir J 32:733–739CrossRefPubMed Garcia-Vidal C, Fernández-Sabé N, Carratalà J et al (2008) Early mortality in patients with community-acquired pneumonia: causes and risk factors. Eur Respir J 32:733–739CrossRefPubMed
6.
go back to reference Austrian R, Gold J (1964) Pneumococcal bacteremia with especial reference to bacteremic pneumococcal pneumonia. Ann Intern Med 60:759–770PubMed Austrian R, Gold J (1964) Pneumococcal bacteremia with especial reference to bacteremic pneumococcal pneumonia. Ann Intern Med 60:759–770PubMed
7.
go back to reference Antunes G, Evans SA, Lordan JL et al (2002) Systemic cytokine levels in community-acquired pneumonia and their association with disease severity. Eur Respir J 20:990–995CrossRefPubMed Antunes G, Evans SA, Lordan JL et al (2002) Systemic cytokine levels in community-acquired pneumonia and their association with disease severity. Eur Respir J 20:990–995CrossRefPubMed
8.
go back to reference Calbo E, Alsina M, Rodríguez-Carballeira M et al (2008) Systemic expression of cytokine production in patients with severe pneumococcal pneumonia: effects of treatment with a β-lactam versus a fluoroquinolone. Antimicrob Agents Chemother 52:2359–2402 Calbo E, Alsina M, Rodríguez-Carballeira M et al (2008) Systemic expression of cytokine production in patients with severe pneumococcal pneumonia: effects of treatment with a β-lactam versus a fluoroquinolone. Antimicrob Agents Chemother 52:2359–2402
9.
go back to reference Fernández-Serrano S, Dorca J, Coromines M et al (2003) Molecular inflammatory responses measured in blood of patients with severe community-acquired pneumonia. Clin Diagn Lab Immunol 10:813–820PubMed Fernández-Serrano S, Dorca J, Coromines M et al (2003) Molecular inflammatory responses measured in blood of patients with severe community-acquired pneumonia. Clin Diagn Lab Immunol 10:813–820PubMed
10.
go back to reference Kellum JA, Kong L, Fink MP et al (2007) Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) study. Arch Intern Med 167:1655–1663CrossRefPubMed Kellum JA, Kong L, Fink MP et al (2007) Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) study. Arch Intern Med 167:1655–1663CrossRefPubMed
11.
go back to reference Menendez R, Martinez R, Reyes S et al (2009) Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia. Thorax 64:587–591CrossRefPubMed Menendez R, Martinez R, Reyes S et al (2009) Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia. Thorax 64:587–591CrossRefPubMed
12.
go back to reference Monton C, Torres A, El-Ebiary M et al (1999) Cytokine expression in severe pneumonia: a bronchoalveolar lavage study. Crit Care Med 27:1745–1753CrossRefPubMed Monton C, Torres A, El-Ebiary M et al (1999) Cytokine expression in severe pneumonia: a bronchoalveolar lavage study. Crit Care Med 27:1745–1753CrossRefPubMed
13.
go back to reference Örtqvist A, Hedlund J, Wretlind B et al (1995) Diagnostic and prognostic value of Interleukin-6 and C-reactive protein in community-acquired pneumonia. Scand J Infect Dis 27:457–462CrossRefPubMed Örtqvist A, Hedlund J, Wretlind B et al (1995) Diagnostic and prognostic value of Interleukin-6 and C-reactive protein in community-acquired pneumonia. Scand J Infect Dis 27:457–462CrossRefPubMed
14.
go back to reference Xu F, Droemann D, Rupp J et al (2008) Modulation of the inflammatory response to Streptococcus pneumoniae in a model of acute lung tissue infection. Am J Respir Cell Mol Biol 39:522–529CrossRefPubMed Xu F, Droemann D, Rupp J et al (2008) Modulation of the inflammatory response to Streptococcus pneumoniae in a model of acute lung tissue infection. Am J Respir Cell Mol Biol 39:522–529CrossRefPubMed
15.
go back to reference Demartini G, Esposti D, Marthyn P et al (2004) Effect of multiple doses of clarithromycin and amoxicillin on IL-6, IFNgamma and IL-10 plasma levels in patients with community-acquired pneumonia. J Chemother 16:82–85PubMed Demartini G, Esposti D, Marthyn P et al (2004) Effect of multiple doses of clarithromycin and amoxicillin on IL-6, IFNgamma and IL-10 plasma levels in patients with community-acquired pneumonia. J Chemother 16:82–85PubMed
16.
go back to reference Choi J, Song M, Kim G et al (2003) Effect of moxifloxacin on production of proinflammatory cytokines from human peripheral blood mononuclear cells. Antimicrob Agents Chemother 47:3704–3707CrossRefPubMed Choi J, Song M, Kim G et al (2003) Effect of moxifloxacin on production of proinflammatory cytokines from human peripheral blood mononuclear cells. Antimicrob Agents Chemother 47:3704–3707CrossRefPubMed
17.
18.
go back to reference Clinical Laboratory Standard Institute (CLSI) (2009) Performance standards for antimicrobial susceptibility testing: 19th informational supplement. CLSI document M100-S18. Wayne, PA: CLSI Clinical Laboratory Standard Institute (CLSI) (2009) Performance standards for antimicrobial susceptibility testing: 19th informational supplement. CLSI document M100-S18. Wayne, PA: CLSI
19.
go back to reference Clinical and Laboratory Standard Institute (CLSI) (2006) Methods for dilution antimicrobial susceptibility test for bacteria that growth aerobically; approved standard, 7th edn. CLSI documentM7-A6. CLSI, Wayne, PA Clinical and Laboratory Standard Institute (CLSI) (2006) Methods for dilution antimicrobial susceptibility test for bacteria that growth aerobically; approved standard, 7th edn. CLSI documentM7-A6. CLSI, Wayne, PA
20.
go back to reference Fine MJ, Auble TE, Yealy DM et al (1997) A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 336:243–250CrossRefPubMed Fine MJ, Auble TE, Yealy DM et al (1997) A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 336:243–250CrossRefPubMed
21.
go back to reference Waterer GW, Somes GW, Wunderink RG (2001) Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 161:1837–1842CrossRefPubMed Waterer GW, Somes GW, Wunderink RG (2001) Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 161:1837–1842CrossRefPubMed
22.
go back to reference Martinez JA, Horcajada JP, Almela M et al (2003) Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 36:389–395CrossRefPubMed Martinez JA, Horcajada JP, Almela M et al (2003) Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 36:389–395CrossRefPubMed
23.
go back to reference Baddour LM, Yu VL, Klugman KP et al (2004) Combination therapy lowers mortality among severely ill patients with pneumococcal pneumonia. Am J Respir Crit Care Med 170:440–444CrossRefPubMed Baddour LM, Yu VL, Klugman KP et al (2004) Combination therapy lowers mortality among severely ill patients with pneumococcal pneumonia. Am J Respir Crit Care Med 170:440–444CrossRefPubMed
24.
go back to reference Rodriguez A, Mendia A, Sirvent JM et al (2007) Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock. Crit Care Med 35:1493–1498CrossRefPubMed Rodriguez A, Mendia A, Sirvent JM et al (2007) Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock. Crit Care Med 35:1493–1498CrossRefPubMed
25.
go back to reference Harbarth S, Garbino J, Pugin J et al (2005) Lack of effect of combination antibiotic therapy on mortality in patients with pneumococcal sepsis. Eur J Clin Microbiol Infect Dis 24:688–690CrossRefPubMed Harbarth S, Garbino J, Pugin J et al (2005) Lack of effect of combination antibiotic therapy on mortality in patients with pneumococcal sepsis. Eur J Clin Microbiol Infect Dis 24:688–690CrossRefPubMed
26.
go back to reference Aspa J, Rajas O, Rodriguez de Castro F et al (2006) Impact of initial antibiotic choice on mortality from pneumococcal pneumonia. Eur Respir J 27:1010–1019PubMed Aspa J, Rajas O, Rodriguez de Castro F et al (2006) Impact of initial antibiotic choice on mortality from pneumococcal pneumonia. Eur Respir J 27:1010–1019PubMed
27.
go back to reference Heumann D, Barras C, Severin A et al (1994) Gram-positive cell wall stimulates synthesis of tumor necrosis factor alpha and interleukin 6 by human monocytes. Infect Immun 62:2715–2721PubMed Heumann D, Barras C, Severin A et al (1994) Gram-positive cell wall stimulates synthesis of tumor necrosis factor alpha and interleukin 6 by human monocytes. Infect Immun 62:2715–2721PubMed
28.
go back to reference Tomasz A, Saukkonen D (1989) The nature of cell wall derived inflammatory components of pneumococci. Pediatr Infect Dis J 8:902–903CrossRefPubMed Tomasz A, Saukkonen D (1989) The nature of cell wall derived inflammatory components of pneumococci. Pediatr Infect Dis J 8:902–903CrossRefPubMed
29.
go back to reference Tuomanen E, Rich R, Zak O (1987) Induction of pulmonary inflammation by components of the pneumococcal cell surface. Am Rev Respir Dis 135:869–874PubMed Tuomanen E, Rich R, Zak O (1987) Induction of pulmonary inflammation by components of the pneumococcal cell surface. Am Rev Respir Dis 135:869–874PubMed
30.
go back to reference Tuomanen E, Vanholder R, De Paepe P et al (1996) Immunomodulating effects of antibiotics: literature review. Infection 24:275–291CrossRef Tuomanen E, Vanholder R, De Paepe P et al (1996) Immunomodulating effects of antibiotics: literature review. Infection 24:275–291CrossRef
31.
go back to reference Blaine T, Pollice P, Rosier R et al (1997) Modulation of the production of cytokines in titanium-stimulated human peripheral blood monocytes by pharmacological agents: the role of camp-mediated signaling mechanism. J Bone Jt Surg 79:1519–1528 Blaine T, Pollice P, Rosier R et al (1997) Modulation of the production of cytokines in titanium-stimulated human peripheral blood monocytes by pharmacological agents: the role of camp-mediated signaling mechanism. J Bone Jt Surg 79:1519–1528
Metadata
Title
Impact of antibiotic therapy on systemic cytokine expression in pneumococcal pneumonia
Authors
S. Padrones
C. Garcia-Vidal
S. Fernández-Serrano
A. Fernández
C. Masuet
J. Carratalà
M. Coromines
C. Ardanuy
F. Gudiol
F. Manresa
J. Dorca
Publication date
01-10-2010
Publisher
Springer-Verlag
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 10/2010
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-010-0993-0

Other articles of this Issue 10/2010

European Journal of Clinical Microbiology & Infectious Diseases 10/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.